Premature mortality attributable to COVID-19: potential years of life lost in 17 countries around the world, January-August 2020.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
09 01 2022
Historique:
received: 02 07 2021
accepted: 05 12 2021
entrez: 10 1 2022
pubmed: 11 1 2022
medline: 14 1 2022
Statut: epublish

Résumé

Understanding the impact of the burden of COVID-19 is key to successfully navigating the COVID-19 pandemic. As part of a larger investigation on COVID-19 mortality impact, this study aims to estimate the Potential Years of Life Lost (PYLL) in 17 countries and territories across the world (Australia, Brazil, Cape Verde, Colombia, Cyprus, France, Georgia, Israel, Kazakhstan, Peru, Norway, England & Wales, Scotland, Slovenia, Sweden, Ukraine, and the United States [USA]). Age- and sex-specific COVID-19 death numbers from primary national sources were collected by an international research consortium. The study period was established based on the availability of data from the inception of the pandemic to the end of August 2020. The PYLL for each country were computed using 80 years as the maximum life expectancy. As of August 2020, 442,677 (range: 18-185,083) deaths attributed to COVID-19 were recorded in 17 countries which translated to 4,210,654 (range: 112-1,554,225) PYLL. The average PYLL per death was 8.7 years, with substantial variation ranging from 2.7 years in Australia to 19.3 PYLL in Ukraine. North and South American countries as well as England & Wales, Scotland and Sweden experienced the highest PYLL per 100,000 population; whereas Australia, Slovenia and Georgia experienced the lowest. Overall, males experienced higher PYLL rate and higher PYLL per death than females. In most countries, most of the PYLL were observed for people aged over 60 or 65 years, irrespective of sex. Yet, Brazil, Cape Verde, Colombia, Israel, Peru, Scotland, Ukraine, and the USA concentrated most PYLL in younger age groups. Our results highlight the role of PYLL as a tool to understand the impact of COVID-19 on demographic groups within and across countries, guiding preventive measures to protect these groups under the ongoing pandemic. Continuous monitoring of PYLL is therefore needed to better understand the burden of COVID-19 in terms of premature mortality.

Sections du résumé

BACKGROUND
Understanding the impact of the burden of COVID-19 is key to successfully navigating the COVID-19 pandemic. As part of a larger investigation on COVID-19 mortality impact, this study aims to estimate the Potential Years of Life Lost (PYLL) in 17 countries and territories across the world (Australia, Brazil, Cape Verde, Colombia, Cyprus, France, Georgia, Israel, Kazakhstan, Peru, Norway, England & Wales, Scotland, Slovenia, Sweden, Ukraine, and the United States [USA]).
METHODS
Age- and sex-specific COVID-19 death numbers from primary national sources were collected by an international research consortium. The study period was established based on the availability of data from the inception of the pandemic to the end of August 2020. The PYLL for each country were computed using 80 years as the maximum life expectancy.
RESULTS
As of August 2020, 442,677 (range: 18-185,083) deaths attributed to COVID-19 were recorded in 17 countries which translated to 4,210,654 (range: 112-1,554,225) PYLL. The average PYLL per death was 8.7 years, with substantial variation ranging from 2.7 years in Australia to 19.3 PYLL in Ukraine. North and South American countries as well as England & Wales, Scotland and Sweden experienced the highest PYLL per 100,000 population; whereas Australia, Slovenia and Georgia experienced the lowest. Overall, males experienced higher PYLL rate and higher PYLL per death than females. In most countries, most of the PYLL were observed for people aged over 60 or 65 years, irrespective of sex. Yet, Brazil, Cape Verde, Colombia, Israel, Peru, Scotland, Ukraine, and the USA concentrated most PYLL in younger age groups.
CONCLUSIONS
Our results highlight the role of PYLL as a tool to understand the impact of COVID-19 on demographic groups within and across countries, guiding preventive measures to protect these groups under the ongoing pandemic. Continuous monitoring of PYLL is therefore needed to better understand the burden of COVID-19 in terms of premature mortality.

Identifiants

pubmed: 35000578
doi: 10.1186/s12889-021-12377-1
pii: 10.1186/s12889-021-12377-1
pmc: PMC8743065
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

54

Informations de copyright

© 2022. The Author(s).

Références

Diabetes Res Clin Pract. 2020 Jul;165:108267
pubmed: 32533988
Nat Med. 2020 Dec;26(12):1919-1928
pubmed: 33057181
Am J Trop Med Hyg. 2020 Aug;103(2):564-569
pubmed: 32484156
Eur J Public Health. 2021 Feb 1;31(1):17-22
pubmed: 33169145
J Immunol. 2017 May 15;198(10):4046-4053
pubmed: 28373583
J Korean Med Sci. 2020 Jun 01;35(21):e199
pubmed: 32476305
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
PLoS One. 2020 Sep 17;15(9):e0238678
pubmed: 32941467
Med Hypotheses. 2020 Nov;144:110160
pubmed: 32795831
J Korean Med Sci. 2020 Aug 17;35(32):e300
pubmed: 32808515
Int J Public Health. 2020 Jul;65(6):719-720
pubmed: 32691080
Am J Public Health Nations Health. 1950 Jan;40(1):17-26
pubmed: 15408636
Euro Surveill. 2020 Jul;25(26):
pubmed: 32643601
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Infect Control Hosp Epidemiol. 2020 Jun;41(6):750-751
pubmed: 32146921
Int J Infect Dis. 2020 Aug;97:267-269
pubmed: 32535304
Health Policy Technol. 2020 Dec;9(4):525-559
pubmed: 32874863
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Front Cardiovasc Med. 2020 Jul 17;7:131
pubmed: 32766284
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Int J Epidemiol. 2022 Feb 18;51(1):35-53
pubmed: 34282450
Int J Environ Res Public Health. 2020 Jun 18;17(12):
pubmed: 32570888
Epidemiology. 1990 Jul;1(4):322-9
pubmed: 2083312
Int J Environ Res Public Health. 2020 Jun 13;17(12):
pubmed: 32545827
J Public Health (Oxf). 2020 Nov 23;42(4):717-722
pubmed: 32894287
Int J Infect Dis. 2020 Apr;93:339-344
pubmed: 32198088
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Wellcome Open Res. 2020 Apr 23;5:75
pubmed: 33709037
Int J Epidemiol. 1977 Jun;6(2):143-51
pubmed: 892979
SN Compr Clin Med. 2020;2(7):874-876
pubmed: 32838138
Viruses. 2019 Feb 20;11(2):
pubmed: 30791586
Cell Death Discov. 2020 May 26;6:37
pubmed: 32499922
Cell Biosci. 2020 Dec 30;10(1):148
pubmed: 33380340
Glob Public Health. 2020 Sep;15(9):1278-1291
pubmed: 32623959

Auteurs

Maider Pagola Ugarte (MP)

University of Nicosia Medical School, Nicosia, Cyprus.

Souzana Achilleos (S)

Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus. achilleos.s@unic.ac.cy.

Annalisa Quattrocchi (A)

Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.

John Gabel (J)

University of Nicosia Medical School, Nicosia, Cyprus.

Ourania Kolokotroni (O)

Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.

Constantina Constantinou (C)

Department of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus.

Nicoletta Nicolaou (N)

Department of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus.

Jose Manuel Rodriguez-Llanes (JM)

European Commission Joint Research Centre, Ispra, Italy.

Qian Huang (Q)

South Carolina Center for Rural and Primary Healthcare, Department of Geography, University of South Carolina, Columbia, USA.

Olesia Verstiuk (O)

Faculty of Medicine 2, Bogomolets National Medical University, Kyiv, Ukraine.

Nataliia Pidmurniak (N)

Faculty of Medicine 2, Bogomolets National Medical University, Kyiv, Ukraine.

Jennifer Wenjing Tao (JW)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Bo Burström (B)

Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

Petra Klepac (P)

Department Communicable Diseases, National Institute of Public Health, Ljubljana, Slovenia.

Ivan Erzen (I)

Public Health School, National Institute of Public Health, Ljubljana, Slovenia.

Mario Chong (M)

Facultad de Ingenieria, Universidad del Pacifico, Lima, Peru.

Manuel Barron (M)

Departamento de Economia, Universidad del Pacifico, Lima, Peru.

Terje P Hagen (TP)

Department of Health Management and Economics, University of Oslo, Oslo, Norway.

Zhanna Kalmatayeva (Z)

Faculty of Medicine, Al Farabi Kazakh National University, Almaty, Kazakhstan.

Kairat Davletov (K)

Health Research Institute, Al Farabi Kazakh National University, Almaty, Kazakhstan.

Inbar Zucker (I)

Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel.

Zalman Kaufman (Z)

Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel.

Maia Kereselidze (M)

National Center for Disease Control and Public Health, Tbilisi, Georgia.

Levan Kandelaki (L)

National Center for Disease Control and Public Health, Tbilisi, Georgia.

Nolwenn Le Meur (N)

University of Rennes, EHESP, REPERES - EA 7449, F-35000, Rennes, France.

Lucy Goldsmith (L)

Population Health Research Institute and Institute for Infection and Immunity, St George's, University of London, London, UK.

Julia A Critchley (JA)

Population Health Research Institute, St George's, University of London, London, UK.

Maria Angelica Pinilla (MA)

Faculty of Medicine, Universidad Cooperativa de Colombia, Villavicencio, Colombia.

Gloria Isabel Jaramillo (GI)

Faculty of Medicine, Universidad Cooperativa de Colombia, Villavicencio, Colombia.

Domingos Teixeira (D)

Ministry of Health and Social Security, Praia, Cape Verde.

Lara Ferrero Goméz (LF)

Department of Nature, Life and Environment Sciences, Jean Piaget University of Cape Verde, Praia, Cape Verde.

Jackeline Lobato (J)

Department of Epidemiology and Biostatistics, Institute of Collective Health (ISC), Fluminense Federal University, Niterói, Brazil.

Carolina Araújo (C)

Graduate Public Health Program, Institute of Studies in Collective Health (IESC), Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Joseph Cuthbertson (J)

Monash University Disaster Resilience Initiative, Monash University, Melbourne, Australia.

Catherine M Bennett (CM)

Institute for Health Transformation, Deakin University, Burwood, Australia.

Antonis Polemitis (A)

University of Nicosia, Nicosia, Cyprus.

Andreas Charalambous (A)

University of Nicosia Medical School, Nicosia, Cyprus.

Christiana A Demetriou (CA)

Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH